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Abstract
Background/Aims: Treatment of chronic hepatitis C (CHC) with pegylated interferon a (pegIFNa) and ribavirin results in a
sustained response in approximately half of patients. Viral interference with IFNa signal transduction through the Jak-STAT
pathway might be an important factor underlying treatment failure. S-adenosyl-L-methionine (SAMe) and betaine
potentiate IFNa signaling in cultured cells that express hepatitis C virus (HCV) proteins, and enhance the inhibitory effect of
IFNa on HCV replicons. We have performed a clinical study with the aim to evaluate efficacy and safety of the addition of
SAMe and betaine to treatment of CHC with pegIFNa/ribavirin.
Methods: In this open-label pilot study, 29 patients with CHC who failed previous therapy with (peg)IFNa/ribavirin were
treated with SAMe, betaine, pegIFNa2b and ribavirin. Treatment duration was 6 or 12 months, depending on genotype, and
the protocol comprised a stopping rule at week 12 if early virological response (EVR) was not achieved. Virological and
biochemical response and safety were assessed throughout the treatment.
Results: 29 patients were enrolled and treated according to the study protocol. 79% of the patients were infected with
genotype 1, 72% had advanced fibrosis, 76% had previously received pegIFNa/ribavirin, and only 14% achieved EVR to the
previous treatment. When treated with the study medications, 17 patients (59%) showed an EVR, only 3 (10%) however
achieved a sustained virological response (SVR). SAMe and betaine were found to be safe when used with pegIFNa/ribavirin.
Conclusion: The addition of SAMe and betaine to pegIFNa/ribavirin improves early virological response in CHC.
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Introduction
Hepatitis C virus (HCV) infection is a major cause of chronic
liver disease worldwide [1]. Chronic hepatitis C (CHC) may lead
to liver cirrhosis and hepatocellular carcinoma. Type I interferons
(IFNs), IFNa and IFNb, are crucial and potent components of the
early host response against virus infection [2] and recombinant
(pegylated) IFNa2a and IFNa2b are widely used for the treatment
of CHC and chronic hepatitis B. The current standard treatment
of CHC with pegylated IFNa (pegIFNa) and ribavirin leads to
cure in about 50% of patients [3,4]. The cause of treatment failure
in the remaining half of the patients is poorly understood. Viral
interference with IFNa signal transduction from the cell surface to
the nucleus is considered an important mechanism behind
ineffective treatment responses.
IFNa binds to the IFNa receptor (IFNAR) on the cell surface
and triggers a signaling pathway that involves the Janus kinases
(Jaks) Jak1 and Tyk2 and the signal transducer and activator of
transcription (STAT) 1, STAT2 and STAT3 [5]. IFNa signaling
through the Jak-STAT pathway ultimately results in transcrip-
tional upregulation of IFN-stimulated genes (ISGs) with potent
antiviral, immunomodulatory and antiproliferative properties. We
have previously shown that expression of HCV proteins in human
osteosarcoma cell lines inhibits IFNa signaling by an upregulation
of the catalytic subunit of protein phosphatase 2A (PP2Ac) [6,7,8].
In line with our in vitro findings, PP2Ac was also over-expressed in
liver extracts of HCV transgenic mice and in liver biopsies of
patients with CHC [8]. An important consequence of the
increased amount of PP2Ac is the inhibition of protein arginine
methyltransferase 1 (PRMT1) [8,9]. PRMT1 catalyzes methyla-
tion of STAT1 [10] as well as of PIAS1 (protein inhibitor of
activated STAT1) [11]. Therefore, inhibition of PRMT1 by
PP2Ac has important consequences for the Jak-STAT signaling
pathway.
PLoS ONE | www.plosone.org 1 November 2010 | Volume 5 | Issue 11 | e15492S-adenosyl-L-methionine (SAMe) is the methyl group donor for
reactions catalyzed by PRMT1. Betaine is required for the
generation of methionine from homocysteine, a reaction that is
central to the recycling of SAMe [12]. We have previously shown
that treatment with SAMe and betaine potentiates IFNa signaling
and enhances the anti-viral efficacy of IFNa in osteosarcoma cells
expressing HCV proteins and in human hepatoma Huh7 cells
harboring an HCV replicon [13]. Furthermore, NS3 helicase
activity and replication of a subgenomic HCV replicon in Huh7.5
cells were found to be inhibited by SAMe treatment [9].
Based on these in vitro findings we hypothesized that addition of
SAMe and betaine to the current standard therapy with pegIFNa
and ribavirin enhances the treatment efficacy in CHC patients




The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1. Male and female patients between 18 and 65 years
with CHC of all HCV genotypes (GTs) and a documented
nonresponse to previous combination treatment with unmodified
IFNa or pegIFNa plus ribavirin were eligible for enrollment.
Eligible patients were identified by a systematic review of patient
charts at the hepatology outpatient clinic of the University
Hospital of Basel, Switzerland. Eligible patients had detectable
HCV RNA in the serum (.12 IU/ml), elevated serum alanine
aminotransferase (ALAT) levels, a liver biopsy taken within 2 years
before the screening visit showing chronic hepatitis and compen-
sated liver disease. Entry neutrophil and platelet counts had to be
at least 1500/ml and 75000/ml, and hemoglobin values at least
Figure 1. Design of the study. Patients were randomized into two groups. Patients in group A received a pre-treatment for one week with SAMe
(1200 mg/day) and betaine (6 g/day), and were then treated for 3 (nonresponders) to 6 (genotypes 2 and 3) or 12 (genotypes 1 and 4) months with a
combination of SAMe, betaine, ribavirin twice daily p.o. at a weight adjusted total daily dose of 800–1200 mg, and pegIFNa2b (1.5 mg/kg) injected s.c.
once per week. Patients in group B received pegIFNa2b and ribavirin during the first week, followed by a combination of pegIFNa2b, ribavirin, SAMe and
betaineat thesamedosesasoutlinedaboveforgroupA.Thefiguredepictstreatmentdurationattheexampleofa patient infectedwithHCVgenotype1.
doi:10.1371/journal.pone.0015492.g001
Table 1. Patient Characteristics.
Patient Number (male/female) 29 (21/8)
Body weight, kg (6 SD) 75.83 (615.15)
Age, years (6 SD) 49.72 (68.84)
ALAT, IU/ml (6 SD) 104 (642)
GGT, IU/ml (6 SD) 184 (6161)
HCV genotype (GT)
GT1, N (%) 23 (79.3%)
GT2, N (%) 2 (6.9%)
GT3, N (%) 2 (6.9%)
GT4, N (%) 2 (6.9%)
Viral load, log10 IU/ml, mean (range) 6.24 (4.52–
7.09)
Fibrosis stage (Metavir)
F1/F2, N (%) 8 (27.6%)
F3, N (%) 5 (17.2%)
F4, N (%) 16 (55.2%)
Previous treatment
Pegylated IFNa/ribavirin 22 (76%)
IFNa/ribavirin 7 (24%)
Response to previous treatment
Primary nonresponse 25 (86%)
Early virological response but no end-of-treatment response 3 (10%)
Week 12 response unknown, but no end-of-treatment response 1 (3%)
doi:10.1371/journal.pone.0015492.t001
SAMe Improves Response to Interferon
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other cause of liver disease, co-infection with human immunode-
ficiency or hepatitis B virus, pregnant women and male partners of
pregnant women, breast feeding women, fertile patients not willing
to use effective contraception, concomitant immunosuppressive
medication, excessive alcohol intake, concomitant malignant neo-
plastic disease, clinically significant psychiatric, metabolic, neuro-
logical, cardiac, renal or endocrine disease, anti-nuclear antibody
titer .1:320, a-fetoprotein .50 mg/l, elevated fasting glucose
level, elevated thyroid-stimulating hormone.
Study Medication
SAMe (Gumbaral 200 mg) was purchased from AWD.pharma
GmbH & Co, D-01445 Radebeul, Germany. Betaine (Cystadane
powder 180 g) was from Orphan Europe, F-92800 Puteaux,
France. Pegylated IFNa2b (PegIntron) and ribavirin (Rebetol
200 mg) were provided by Essex Chemie AG, Luzern, Switzer-
land. All study drugs were stored and distributed by the hospital
pharmacy of the University Hospital Basel, Switzerland.
Study Design
This single-center study was performed at the University
Hospital Basel, Switzerland, Division of Gastroenterology and
Hepatology. It was designed as a pilot study to test the efficacy and
safety of a combination treatment with pegIFNa2b, ribavirin,
SAMe and betaine in patients with CHC who did not respond to a
previous therapy with (peg)IFNa and ribavirin. The primary
endpoints was sustained virologic response (no HCV RNA
detectable 24 weeks after the end of treatment). The secondary
endpoint was early virologic response after 12 weeks of therapy
with pegIFNa2b, ribavirin, SAMe and betaine. Patients were
randomized into one of two treatment groups (Figure 1). Patients
in group A received a pre-treatment with SAMe 400 mg three
times daily p.o. (1200 mg/day) and betaine 3 g twice daily p.o.
(6 g/day) for one week, and were then treated for 3 to 12 months
with a combination of SAMe, betaine, ribavirin twice daily p.o. at
a weight adjusted total daily dose of 800 mg (,65 kg body
weight), 1000 mg (65–85 kg) or 1200 mg (.85 kg), and pegIF-
Na2b (1.5 mg/kg bodyweight) injected s.c. once per week. Patients
in group B received pegIFNa2b and ribavirin during the first
week, followed by a combination of pegIFNa2b, ribavirin, SAMe
and betaine at the same doses as outlined above for group A.
Treatment was discontinued after 12 weeks in patients who did not
achieve early virological response (EVR), defined as a reduction of
HCV viral load (VL) by .2 log10 IU/ml from baseline (BL).
Duration of treatment was dependent on HCV GT and was
Figure 2. Effect of pretreatment with SAMe and betaine on HCV viral load. A) HCV viral load (VL) at baseline (BL) was slightly higher in
group A than group B (6.51 versus 6.0 log10 IU/ml, t-test p=0.017). Shown is a box plot diagram. B) In group A, no significant effect of SAMe and
betaine pretreatment on HCV VL was observed after one week. C) Reduction in HCV VL compared to the BL value (in log10 IU/ml) during the first 12
weeks of treatment in group A (dark grey bars) and group B (light grey bars). VL reduction was significantly different at day 1 and 2, but not at later
time points (unpaired t-test, p=0.03 at d1, p=0.04 at d2).
doi:10.1371/journal.pone.0015492.g002
SAMe Improves Response to Interferon
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patients had a follow-up (FU) visit 24 weeks after the end of
treatment.
Patients were evaluated as outpatients for safety, tolerance, and
efficacy at the start of the therapy (d-7 of group A; d0 of group B), at
24 h (d1), 48 h (d2), 96 h (d4) and 144 h (d7) after the first injection
of pegIFNa2b. Further evaluations during the combination therapy
were at weeks 2 (w2), w4, w8, w12, w24 and w48, and at FU (w72)
24 weeks after the end of treatment (Figure 1). HCV RNA was
quantified with the COBASH AmpliPrep Taqman HCV-Test from
Roche Molecular Systems according to the manufacturer’s
instructions. HCV genotyping was performed by reverse hybrid-
ization (Inno Lipa HCV, Innogenetics, Gent, Belgium). Histopath-
ological grading and staging of the HCV liver biopsies according to
the Metavir classification system was performed at the Pathology
Institute of the University Hospital Basel.
Adverse events were documented throughout the study duration.
Ethics Statement
The study was approved by the ethics committee of the Kanton
Basel and by Swissmedic and was carried out according to the
Declaration of Helsinki and the International Conference on
Harmonisation/Committee for Proprietary Medicinal Products
(ICH/CPMP) guidelines ‘‘Good Clinical Practice’’. All patients
gave written informed consent before enrollment. The study
conduct was monitored by KMS Kammermann Monitoring
Services GmbH, Zug, Switzerland. The study was registered at
ClinicalTrials.gov under the registration number NCT00310336.
Results
Characteristics of the Patients
25 male and 8 female patients between 30 and 64 years of age,
all Caucasians, were screened and enrolled in the study from
October 2006 to April 2008. All patients had been previously
treated in the hepatology outpatient clinic of the University
Hospital of Basel. 16 patients were randomized into group A,
and 17 into group B (see Figure 1). The randomization was
performed in two separate groups for GTs 1/4 and for GTs 2/3. 2
male patients, both randomized into group A, withdrew their
consent before the first application of study medication. One male
patient from group A discontinued treatment after 4 days, and
another male patient from group B withdrew from the study 2
weeks after treatment initiation. The remaining 29 patients were
treated according to the protocol with the exception of two
patients (#18 and #20) who received a liver transplant after 5 and
9 months of therapy because of development of hepatocellular
carcinoma. The baseline characteristics of the 29 study patients
are shown in Table 1. 23 patients were infected with HCV GT1
(79%), and 2 each with GT2 (7%), GT3 (7%) and GT4 (7%). The
mean VL was 6.24 log10 IU/ml. 21 patients (72%) had advanced
fibrosis(Metavir stages3 or 4), 16 patients(55%) were cirrhotic. 76%
ofthe patients hadpreviouslybeentreatedwithpegylated IFNa2aor
-2b and ribavirin, whereas the remaining 24% had a previous
treatment with standard IFNa2a or -2b and ribavirin (Table 1).
Only 3 patients had had an EVR without end-of-treatment response
(EoTR) to the previous treatment, whereas the majority of the
patients (86%) had had less than 2 log10 reduction of VL within the
first 12 weeks of the previous treatment (primary nonresponse,
PNR). For one female patient there was no week 12 VL available
from the previous treatment, she however showed an EoT
nonresponse (EoTNR). Patients in group A were not significantly
different from patients in group B in any of the characteristics listed
in Table 1, except for VL at baseline (Figure 2A).
Virological and Biochemical Response to SAMe and
Betaine
To test whether SAMe and betaine have an effect on VL and
liver enzyme values that is independent from pegIFNa and
ribavirin, patients in group A were pre-treated for one week with
SAMe and betaine only. There was no significant decrease in VL
in response to SAMe and betaine (Figure 2B), and no significant
effect on ALAT serum levels (data not shown). The mean
reduction of VL for both treatment groups at days 1, 2, 4, and 7
and at weeks 2, 4, 8 and 12 is shown in Figure 2C. Group A
(pretreatment with SAMe and betaine) had a slightly more
pronounced reduction of VL in the first 48 h of combination
treatment (unpaired t-test; p=0.03 for d1; p=0.04 for d2), there
Figure 4. Viral load in 2 patients with rapid virological response to pegIFNa2b, ribavirin, SAMe and betaine. 2 patients showed an RVR
to the study treatment (color code = blue), both had no virological response in the previous treatment. Both patients had an SVR. The left panel
shows VL during the first 12 weeks of the previous treatment. The right panel shows VL during the study therapy. Indicated on the left from top to
bottom are treatment group (A or B), sex (m or f), age at the start of the therapy, GT and Metavir fibrosis stage. The previous treatment (either
pegIFNa/ribavirin oder IFNa/ribavirin) is indicated on top of the left panel.
doi:10.1371/journal.pone.0015492.g004
Figure 3. Viral load in 12 patients with nonresponse to pegIFNa2b, ribavirin, SAMe and betaine. 12 patients had no virological response
to the study medication (Primary non-response, PNR, color code = grey). The left panel shows VL during the first 12 weeks of the previous treatment.
The right panel shows VL during the study therapy. Indicated on the left from top to bottom are treatment group (A or B), sex (m or f), age at the start
of the therapy, GT and Metavir fibrosis stage. The previous treatment (either pegIFNa/ribavirin oder IFNa/ribavirin) is indicated on top of the left
panel.
doi:10.1371/journal.pone.0015492.g003
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groups (A and B) at later time points, and even the significant
results at early time points have to be interpreted with caution,
given the fact that baseline VL was higher in group A.
Virological and Biochemical Response to Treatment with
PegIFNa2b, Ribavirin, SAMe and Betaine
Twelve patients (41%) did not achieve an EVR with the study
combination treatment (Figure 3), and therapy was discontinued
after 12 weeks. The remaining 17 patients (59%) showed an initial
virological response, although 14 formerly had a documented
PNR in their previous treatment. Two patients (patients #3 and
#14) now showed rapid virological response (RVR) with
undetectable HCV-RNA after 4 weeks of the study treatment,
and both had SVR in follow-up (Figure 4). Four patients had
negative HCV RNA after 12 weeks of study treatment (complete
EVR; cEVR), and one of them (#25) completed study treatment
with a SVR (Figure 5). The other 3 patients relapsed either on
treatment (#23) or during follow-up (#16, #33). All 4 cEVR
patients were cirrhotic, and 3 of them had been previously treated
with pegIFNa2 and ribavirin (Figure 5). The remaining eight
patients with previous PNR had an EVR at week 12 of study
combination therapy (Figure 6). However, only two of them
became HCV RNA negative on treatment, and none of them had
an SVR. Finally, there were three patients who had achieved an
EVR but no EoTR in their previous treatments with (peg)IFNa2
and ribavirin (Figure 7). All of them again showed an EVR.
Study treatment had to be discontinued however in patients #18
and #20 because they were liver transplanted during the study (at
months 5 and 9 of treatment, respectively).
Hence, 15 patients with an initial response (either RVR or
cEVR or EVR) to the study medication completed the treatment
according to the study protocol. All together, 3 of these 15 patients
had an SVR, 4 had an EoTR but relapsed during FU, and 8 had
no EoTR.
The biochemical response in the patients with an initial
response to pegIFNa2b, ribavirin, SAMe and betaine combination
therapy was more pronounced than in the PNR patients
(Figure 8). At week 12 of the treatment, only 1 of the 12 PNR
patients, but 7 of the 17 patients with an EVR had normal ALAT.
Adverse Events and Dose Modification
The patients reported side effects such as flu-like symptoms (17
patients), Fatigue (11), myalgias and arthralgias (11), dry skin (10),
moodiness and depression (9), diarrhea (8), chills and shivering (8),
fever (6), abdominal pain and cramps (6), headache (6), loss of
appetite (4), nausea (3), dizziness (3), exertional dyspnea (3),
alopezia (2), cough (1) and sleep disturbances (1), that did not differ
from the ones usually observed in pegIFNa and ribavirin
treatments. No unexpected or unusual adverse events occurred
during the entire study. No adverse events occurred during the
first 7 days of treatment with SAMe and betaine in patients from
group A. Hemoglobin, platelets and neutrophils decreased during
therapy as is expected for pegIFNa and ribavirin combination
treatments. The pegIFNa dosage was reduced in 4 patients (by
20 mg/week in patients #3, #5 and #7, and by 38 mg/week in
patient #23). The ribavirin dosage was reduced in 2 patients, from
1000 mg/day to 800 mg/day (patient #13) and from 1200 mg/
day to 1000 mg/day (patient #16).
Discussion
This pilot trial included 29 patients who had previously failed a
combination therapy with (peg)IFNa and ribavirin. 17 (59%) of
these patients now had an EVR when re-treated with pegIFNa2b,
ribavirin, SAMe and betaine (Figure 9). The addition of SAMe
and betaine to the current standard combination therapy therefore
achieved an EVR rate that was considerably higher than reported
before in trials investigating re-treatment of patients with pre-
vious nonresponse and relapse. The recently published EPIC trial,
investigating response to pegIFNa2b/ribavirin therapy in 2293
patients with previous (peg)IFNa/ribavirin therapy failure, showed
that overall 36% of the patients achieved an EVR [14]. EPIC,
importantly, not only included nonresponders (61%), but also at
Figure 5. Viral load in 4 patients with a complete early virological response to pegIFNa2b, ribavirin, SAMe and betaine. 4 patients
with a cEVR to the study treatment (color code = green), all of them previous nonresponders. Patient #25 had an SVR.
doi:10.1371/journal.pone.0015492.g005
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of relapse patients has consistently resulted in higher SVR rates
than re-treatment of nonresponders [14,15,16,17,18]. Moreover,
37% of the patients included in EPIC had previously been treated
with standard IFNa/ribavirin. In our trial we only included
nonresponders, 86% of which even had documented PNR at week
12 of the previous treatment, and 76% had been treated with
pegIFNa/ribavirin (only 24% with IFNa/ribavirin).
Taken together, the 59% EVR rate in our difficult-to-treat
group of patients suggests that the addition of SAMe and betaine
to pegIFNa2b/ribavirin improves EVR rates in patients with
CHC.
Despite the high rate of EVR in our trial, only 3 patients (10%)
achieved an SVR. 4 additional patients achieved an EoTR but
then relapsed during FU. 10 of the 17 EVR patients, however,
either never reached negativity for HCV RNA or had a viral
breakthrough during therapy. Overall, only 17% of the patients
with an EVR showed later SVR in our study. Other re-treatment
studies reported higher SVR rates (49% [15]; 36% [16]) in
patients who had an EVR during re-treatment with pegIFNa/
ribavirin. In EPIC, an SVR was observed in 56% of the patients
who were HCV RNA negative at week 12 (cEVR), in 12% of the
patients with an EVR but still detectable HCV-RNA at week 12,
and in none of the patients without EVR [14]. In our small pilot
Figure 6. Viral load in 8 patients with an early virological response to pegIFNa2b, ribavirin, SAMe and betaine. 8 patients had .2 log
reduction of VL after 12 weeks of combination treatment but had still detectable HCV RNA (EVR, color code = yellow). All of them had been previous
nonresponders. No patient in this group had an SVR.
doi:10.1371/journal.pone.0015492.g006
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of the patients with an EVR (and still detectable HCV RNA at
week 12). Because of the heterogeneity of these clinical trials it is
difficult to directly compare the results. However, the overall low
SVR rate in our EVR patients suggests that SAMe and betaine are
only effective early in the treatment. It is conceivable that adaptive
mechanisms in hepatocytes restore intracellular SAMe concentra-
tions to pre-treatment levels, because SAMe is involved in many
enzymatic reactions and its concentration is regulated by numerous
metabolic pathways.
Tachyphylaxis to SAMe might be overcome by increasing the
dosage, but in this small pilot study, we were not able to evaluate
the effectiveness of different doses of SAMe and betaine. SAMe
was given at a dose of 1200 mg per day because the same dosage
was used and found to be safe during a treatment period of two
years in the largest study published using SAMe [19]. Likewise,
betaine treatment with 6 g per day has been previously shown to
be effective and safe [20]. Future studies should aim to define the
optimal dosages for SAMe and betaine.
The rationale for adding SAMe to pegIFNa/ribavirin treat-
ments is based on our previous analysis of HCV interference with
IFNa signaling in cultured cells, transgenic mice and liver biopsies
from patients with CHC [6,8,9,13,21]. Using cell lines with
inducible expression of HCV proteins and using the HCV replicon
system we showed that SAMe improves methylation of the IFNa
induced transcription factor STAT1 and its binding to DNA
response elements, thereby increasing the induction of ISGs and
enhancing the inhibitory effect of IFNa on replicons [13]. In the
Figure 7. Viral load in response to pegIFNa2b, ribavirin, SAMe and betaine in 3 patients with an EVR in their previous treatment. 3
patients had achieved an EVR in their previous treatment, but no EoTR. They all achieved EVR when re-treated with the study medication. None of
them had an SVR.
doi:10.1371/journal.pone.0015492.g007
Figure 8. Biochemical response to study medication. Shown are box plot diagrams of the ALAT values at baseline (BL), week 4 (w4), w12, w24,
w48 and follow up (FU) in 12 patients without response to the study medication (left panel) and 17 patients with an EVR (right panel). The blue line
shows the upper limit of normal.
doi:10.1371/journal.pone.0015492.g008
SAMe Improves Response to Interferon
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betaine on IFNa signal transduction in the liver of the patients.
Consequently, we cannot exclude that SAMe and betaine improve
the response to pegIFNa/ribavirin treatments by mechanisms that
differ from our proposed model of action that involves methylation
of STAT1 as the key event.
Betaine was added to the combination treatment in order to
prevent the accumulation of the toxic SAMe metabolite S-
adenosyl-L-homocysteine (AdoHcy) and to further increase the
intracellular concentrations of SAMe [12,22]. We did not measure
the plasma levels of homocysteine or betaine, and therefore cannot
assess the effect of betaine on SAMe metabolism in our patients.
A number of directly acting antiviral agents is presently in
advanced stages of clinical development. The most promising
candidates include direct inhibitors of the HCV NS3 protease such
as telaprevir [23], boceprevir [24] and MK-7009 [25], as well as
both nucleoside and non-nucleoside inhibitors of the NS5B RNA-
dependent RNA polymerase. Although these agents have
demonstrated potent antiviral effectiveness, monotherapy has
been complicated by rapid virological breakthrough due to the
selection of drug-resistant mutants. To prevent viral resistance,
protease and polymerase inhibitors are used only in combination
with pegIFNa/ribavirin in phase II and III clinical studies.
However, a substantial number of patients do not respond to
pegIFNa, most likely because their endogenous IFN system is
already induced before therapy, and because of HCV interference
with IFNa signal transduction through the Jak-STAT pathway
[6,8,21,26,27,28]. Such patients might be at risk for viral
breakthrough and resistance development even when receiving a
triple combination therapy (protease inhibitor plus pegIFNa/
ribavirin). The 4 weeks of lead-in phase with pegIFNa/ribavirin
used in SPRINT-1 and in ongoing boceprevir trials will exclude
those flat nonresponders from the triple combination therapy, and
will help to reduce the emergence of resistant viruses [24]. The
addition of SAMe and betaine to the initial phase of such a
treatment could be a reasonable strategy. By improving the
cellular response to pegIFNa, SAMe and betaine have the
potential to increase the number of patients who achieve an
initial response and can be offered triple combination therapies.
In conclusion, addition of SAMe and betaine to the current
standard therapy with pegIFNa/ribavirin resulted in an EVR in
59% of patients who previously were nonresponders to (peg)
IFNa/ribavirin therapies. SAMe and betaine had an excellent
safety and tolerability profile. The improvement of response to
pegIFNa/ribavirin, when combined with SAMe and betaine,
should encourage further studies, since pegIFNa and ribavirin will
be cornerstones of CHC treatments for many years to come.
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